Mid-stage testing is underway for Eli Lilly’s new weight-loss combination, and the preliminary results appear promising, though the company could be facing trouble with side effects.
Zepbound, a GLP-1 blockbuster from the drugmaker, was combined with eloralintide, which targets the amylin hormone, in patients living with obesity and type 2 diabetes. The combination therapy’s highest dose group showed weight loss of 23.3%, per data presented Wednesday at the annual meeting of the European Association for the Study of Diabetes, after 48 weeks.
The combined effect greatly exceeds what either component delivers on its own. Participants who took only Zepbound shed 14.8%, whereas those who took the highest dose of eloralintide alone lost 11.1%.
Combining Two Hormonal Pathways
Eloralintide aims at the amylin hormone. When paired with Zepbound, Lilly is joining a GLP-1 agonist with a drug that targets a distinct hormonal pathway.
Zepbound has become a major product in the field of weight-loss drugs, which now centers around the GLP-1 class. Adding amylin signaling to the mix seems to strengthen its impact.
The Dropout Problem
The results were also notable because patients with diabetes don’t tend to lose as much weight on medications as those who don’t have diabetes. That difference makes the trial’s outcome more striking than it would be otherwise.
The trial’s results show that people with diabetes can overcome their usual trouble shedding pounds through medicine. The 23.3% weight loss seen after 48 weeks stands out as a strong result, especially for a group that has historically not responded well to weight-loss medications.
There is a drawback, however. When high numbers of patients stop taking the treatment, it can cast doubt on how well they tolerate it. The dropout rate was notably high during the study.
High rates of people stopping the treatment may raise questions about its tolerability.
The outcome delivered a notable reduction in body mass — 23.3% — even as it pushed participants away from the regimen. This contradiction sits at the heart of what these findings raise.
The Race Is On
Lilly is competing to bring new weight-loss drugs to the marketplace. It is not the only player in that race — though the source does not describe the field beyond noting the GLP-1 class’s prominence.
Zepbound has already become a blockbuster. Adding eloralintide expands its scope to a new hormonal target, and the mid-stage results point toward the combination performing well.
Lilly will need to weigh how well the drug performs against the side effects it causes as the program moves forward, since a treatment that works well but pushes patients away is not sustainable. The question now is whether the tolerability problems can be handled at all.
What the Data Show
The key facts from the trial:
- Weight loss at 48 weeks: 23.3% at the highest combination dose
- Zepbound alone: 14.8% weight loss
- Eloralintide alone: 11.1% weight loss
- Trial stage: Mid-stage
- Presentation: Wednesday at the European Association for the Study of Diabetes
That 23.3% figure is the key statistic. It outperforms both individual parts on their own, and it also exceeds the past results for diabetes patients taking weight-loss medications.
The Bottom Line
What matters most is how well these two parts work together. A 23.3% weight loss seen after just 48 weeks stands as proof of that combined strength, with the numbers clearly showing an advantage that neither part could claim on its own.
The problem of people dropping out of the treatment can’t simply be set aside. High rates of withdrawal raise questions about how well the drug is tolerated, and Lilly will need to face those questions directly as the program moves forward.
So far, the results look promising. The pairing of two separate hormonal pathways seems to be delivering on its promise, and the weight-loss numbers back up that approach.
The unresolved tolerability issues stand as the central obstacle to this promising mid-stage result becoming a marketed product rather than a footnote in the history of obesity research.
See the a run of 35 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.